Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

This randomized, multicenter study compared the efficacy of docetaxel with or without capecitabine following fluorouracil/epirubicin/cyclophosphamide (FEC) therapy in operable breast cancer and investigated the role of Ki67 as a predictive biomarker. Patients were randomized to 4 cycles of docetaxel...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohno, S., Chow, L. W. C., Sato, N., Masuda, N., Sasano, H., Takahashi, F., Bando, H., Iwata, H., Morimoto, T., Kamigaki, S., Nakayama, T., Nakamura, S., Kuroi, K., Aogi, K., Kashiwaba, M., Yamashita, H., Hisamatsu, K., Ito, Y., Yamamoto, Y., Ueno, T., Fakhrejahani, E., Yoshida, N., Toi, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825616/
https://www.ncbi.nlm.nih.gov/pubmed/24122389
http://dx.doi.org/10.1007/s10549-013-2691-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825616/
https://www.ncbi.nlm.nih.gov/pubmed/24122389
http://dx.doi.org/10.1007/s10549-013-2691-y

Ejemplares similares